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An attenuation of the HIV-1 replication capacity (RC) has been observed for immune-mediated escape mutations in Gag re-
stricted by protective HLA alleles. However, the extent to which escape mutations affect other viral proteins during natural in-
fection is not well understood. We generated recombinant viruses encoding plasma HIV-1 RNA integrase sequences from anti-
retroviral-naïve individuals with early (n 88) and chronic (n 304) infections and measured the in vitro RC of each. In
contrast to data from previous studies of Gag, we observed little evidence that host HLA allele expression was associated with
integrase RC. A modest negative correlation was observed between the number of HLA-B-associated integrase polymorphisms
and RC in chronic infection (R0.2; P 0.003); however, this effect was not driven by mutations restricted by protective HLA
alleles. Notably, the integrase variants S119R, G163E, and I220L, which represent uncommon polymorphisms associated with
HLA-C*05, -A*33, and -B*52, respectively, correlated with lower RC (all q< 0.2). We identified a novel C*05-restricted epitope
(HTDNGSNF114 –121) that likely contributes to the selection of the S119R variant, the polymorphism most significantly associ-
ated with lower RC in patient sequences. An NL4-3 mutant encoding the S119R polymorphism displayed a35%-reduced func-
tion that was rescued by a single compensatory mutation of A91E. Together, these data indicate that substantial HLA-driven at-
tenuation of integrase is not a general phenomenon during HIV-1 adaptation to host immunity. However, uncommon
polymorphisms selected by HLA alleles that are not conventionally regarded to be protective may be associated with impaired
protein function. Vulnerable epitopes in integrase might therefore be considered for future vaccine strategies.
HIV-1 in vitro replication capacity (RC) can be impairedthrough the selection of human leukocyte antigen (HLA)
class I-restricted CD8 cytotoxic T-lymphocyte (CTL) escape
mutations (20, 24, 25, 48). This phenomenon is most notable for
mutations of the Gag protein (8, 41, 50, 59) that lie within CTL
epitopes restricted by protective HLA class I alleles, such as HLA-
B*13 (29), HLA-B*27 (55), HLA-B*51 (34), HLA-B*57 (6, 9), and
HLA-B*81 (64). Using recombinant viral approaches, we have
observed HLA-associated reductions in RC for patient-derived
Gag-protease sequences (8). Notably, significant Gag RC defects
were seen in the context of protective HLA class I alleles during
acute/early infection but not during chronic infection, most likely
due to the accumulation of compensatory mutations (8). Protec-
tive HLA allele-associated viral attenuation has also been demon-
strated by usingGag sequences obtained from spontaneousHIV-1
controllers (42, 46), suggesting that immune-mediated fitness de-
fects contribute to this rare phenotype (39, 43, 66).
The extent to which host immune pressure on regions outside
Gag can affect RC in naturally occurring HIV-1 sequences re-
mains incompletely known. A limited number of reports by our
group and others have investigated the impact of CTL escape mu-
tations in reverse transcriptase (RT)-integrase (16), Nef (60), and
envelope (59). However, no studies to date have assessed this
question using large, well-powered, population-based analyses.
An improved understanding of HIV-1 adaptation to host immu-
nity and its consequence for viral replicative fitness may reveal
important epitopes that can assist in the development of vaccines
designed to target the most vulnerable regions of HIV-1.
The HIV-1 integrase protein is a highly conserved 32-kDa en-
zyme that plays an essential role in the viral life cycle by catalyzing
the 3=DNA-processing and strand transfer reactions that result in
the covalent ligation of the viral genome into the host cell chro-
mosome (19, 37). It is therefore a critical target for new antiviral
therapies (45, 49). Viral fitness defects resulting frommutations in
the Pol gene following antiretroviral therapy are well documented
(30, 51, 61), and the raltegravir resistance mutations N115H and
Q148H in integrasewere associated recentlywith reduced viral RC
(30). Integrase is also a target for CTL responses, and it encodes a
number of immunogenic epitopes restricted by protective HLA
class I alleles, including B*27 (47), B*51 (38, 58), and B*57/B*58
(1, 53). T-cell responses against integrase are often detectable in
individuals with reduced viral loads (44). Moreover, certain inte-
grase epitopes are known to be targeted early following infection
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(3, 57) and exhibit strong and reproducible patterns of immune
escape at the population level (15).
We have demonstrated previously thatHLA-associated RC de-
fects occur in RT-integrase sequences obtained from HIV-1 elite
controllers (12); however, the integrase protein has not been eval-
uated systematically for evidence of immune-mediated attenua-
tion or as a potential target for vaccine design. In order to examine
the impact of HLA-associated immune pressure on HIV-1 inte-
grase function, we investigated the in vitro RC of recombinant
viruses expressing patient-derived sequences obtained from indi-
viduals during early and chronic infections. Our results demon-
strate that mutations in integrase-derived CTL epitopes restricted
by HLA class I alleles that are not typically considered to be pro-
tective can attenuate HIV-1 replication.
MATERIALS AND METHODS
Patients and samples. Samples fromantiretroviral-naïve individuals with
early infection (n 88; median time postinfection, 77 days [interquartile
range {IQR}, 54 to 90]) were obtained from Acute Infection and Early
Disease Research Program (AIEDRP) sites in the United States and Aus-
tralia (n 25) (12), a privatemedical clinic inGermany (n 21) (12), and
the Vancouver Injection Drug Users study (n  42) (63). Of these, 9
individuals (10%) had positive HIV RNA (5,000 copies/ml) or detect-
able serump24 antigen but a negativeHIV-1 enzyme immunoassay (EIA)
result, 27 (31%) had a positive EIA result but a negative or indeterminate
Western blot result, and 52 (59%) had a negative EIA result during the
previous 6 months or a negative detuned EIA result (33) at enrollment.
These categories are comparable to Fiebig stages 1/2, 3/4/5, and 6, respec-
tively (21). Infection dates were estimated as follows (12). For HIV RNA-
positive (RNA)/EIA-negative (EIA) patients, 4 weeks were subtracted
from the date of the negative EIA. For patients with a positive EIA result
but a negative/indeterminateWestern blot result, 6 weeks were subtracted
from the date of the positive EIA. For patients with a negative detuned EIA
result, 4 months were subtracted from this date. For the remainder of the
patients, infection dates were estimated as the midpoint between the last
negative and the first positive EIA result. Clinical histories were incorpo-
rated into infection date estimates if available.
For the chronic infection cohort, samples (n  304) were obtained
from the baseline (antiretroviral-naïve) time point of theHOMERcohort,
which is composed of individuals initiating their first highly active anti-
retroviral therapy (HAART) regimen in British Columbia, Canada (13,
15). Time since infection is unknown for these individuals. Clinical char-
acteristics of patients with early and chronic infections are provided in
Table 1.
All patients were HLA class I typed by using sequence-based methods
(12, 14). Ethical approval was obtained through the relevant institutional
review boards.
Construction of recombinant viruses. Recombinant viruses encod-
ing patient-derived integrase sequences were generated on an NL4-3
background as described previously (8, 16), with the following modifica-
tions. HIV-1 integrase was RT-PCR amplified from plasma HIV RNA
using sequence-specific, subtype B-optimized primers. Second-round
PCR was performed by using PAGE-purified primers (forward primer
5=-AAAGGAAAAAGTCTACCTGGCATGGGTACCAGCACACAA
AGG AAT TGG AGG AAA TGA ACA AGT AGA TAA ATT GGT CAG
TGC TGG AAT CAG GAA AGT ACT A-3= and reverse primer 5=-ACT
TATTTTTGGATTAGTACTTTCATAGTGATGTCTATAAAACCA
GTCCTTAGCTTTCCTTGAAATATACATATGGTGTTTTACTAA
TCTTTTCCATG-3=). These primersmatch theNL4-3 sequence directly
upstream and downstream of integrase and are designed to facilitate the
homologous recombination of the PCR product and the pNL4-3 back-
bone sequence (see below).
Plasmid pNL4-3integrase was developed by inserting unique BstEII
restriction sites at the 5= and 3= ends of the integrase gene (HXB2 nucle-
otide positions 4229 and 5093, respectively), using theQuikChangeXL kit
(Stratagene). This was followed by the deletion of the entire integrase
coding sequence using BstEII digestion (New England BioLabs) and gel
purification. Plasmid pNL4-3integrase was religated by using T4 DNA
ligase (New England BioLabs) and maintained in Stbl3 Escherichia coli
cells (Invitrogen). To generate recombinant viruses, 10 g of BstEII-lin-
earized pNL4-3integrase plus 50 l of a second-round amplicon (ap-
proximately 5 g) were mixed with 2.0  106 CEM-derived GXR25 re-
porter T cells (10) in 800 l of Mega-Cell medium (Sigma) and
transfected by electroporation using a Bio-Rad GenePulser II instrument
in single cuvettes (exponential protocol of 300 V and 500 F) or using a
Bio-RadMxCell_Pro instrument with 96-well electroporation plates (ex-
ponential protocol of 250 V and 2,000 F). Following transfection, cells
were rested for 15 min at room temperature, transferred into 25-cm2
flasks in 5 ml of R20 medium (RPMI 1640 containing 20% fetal calf
serum [FCS], 2 mM L-glutamine, 100 units/ml penicillin, and 100 g/ml
streptomycin), and fed with 5 ml R10 medium on day 5 and with re-
placement thereafter. Tat-driven green fluorescent protein (GFP) expres-
sionwasmonitored by flow cytometry (FACSCalibur [BDBiosciences] or
Guava 8HT [Millipore]) starting on day 12, as described previously (10).
Once the GFP-positive (GFP) expression level reached 15% among
viable cells, supernatants containing the recombinant viruses were har-
vested, and aliquots were stored at80°C.
Replication capacity assays. Viral titers and replication capacity (RC)
assays were performed as described previously, using the GXR25 reporter
T-cell line (8, 42). RC assays were initiated at a multiplicity of infection
(MOI) of 0.003 and included one negative control (uninfected cells only)
and one positive control (NL4-3 integrase reintroduced into the NL4-
3integrase backbone using identical methods) per 24-well plate. Assays
typically featured four to six 24-well plates, each containing 22 recombi-
nant viruses, one positive control, and one negative control. For each
virus, the natural log slope of the percentage of GFP cells was calculated
during the exponential phase of viral spread (days 3 to 6). This value was
divided by the mean rate of spread of all NL4-3 controls to generate a
normalized, quantitative measure of RC. RC values of	1.0 or1.0 indi-
cate rates of spread that were lower than or higher than those of NL4-3,
respectively. Each virus was assayed in a minimum of two independent
experiments, and average replication rates are reported. Previously re-
ported quality control experiments confirmed that RC values of indepen-
dently generated bulk (i.e., quasispecies-containing) recombinant viruses
were highly concordant for a given patient sample and that the reintro-
duction of cloned NL4-3 sequences into an NL4-3 backbone did not alter
viral fitness compared to that of the parental NL4-3 strain (8).
Sequence analysis.Bulk plasmaHIV-1RNA integrase sequences from
individuals early in infectionwere collected by using standardmethods, as
described previously (15). Briefly, HIV-1 RNA was extracted from 200 to
500 l of plasma by using the QIAamp viral RNA kit (Qiagen) or the
NucliSENS easyMag system (bioMérieux), amplified by nested RT-PCR
using sequence-specific primers, and sequenced bidirectionally on an ABI
3730xl sequencer (Applied Biosystems). Chromatograms were analyzed
TABLE 1 Clinical characteristicsa
Parameter
Median value (IQR) for group
Early cohort
(n 88)
Chronic cohort
(n 304)
Plasma viral load (log10 copies/ml) 5.26 (4.48–5.88)
b 5.16 (4.95–5.51)
CD4 cell count (cells/mm3) 522 (406–760)c 285 (140–423)
CD8 cell count (cells/mm3) 881 (712–1153)d NA
Estimated time since infection (days) 77 (64–90) NA
a All values reported as medians (IQR). NA, not available.
b Clinical data were available for 43 individuals.
c Clinical data were available for 37 individuals.
d Clinical data were available for 36 individuals.
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by using Sequencher 4.9 (Gene Codes) or the custom software RECall
(11). Nucleotide mixtures were called where the secondary peak height
exceeded 25%of the dominant peak height. All sequences were confirmed
as subtype B sequences by comparison to reference sequences (http:
//www.hiv.lanl.gov). Nucleotide alignments were performed by using a
modified NAP algorithm (32). Bulk HIV-1 RNA sequences were previ-
ously collected by using comparable methods for the chronic infection
cohort (15). In addition, HIV-1 RNAs from all recombinant viral stocks
were extracted from culture supernatants, amplified by nested RT-PCR,
and resequenced to confirm patient origin and to assess viral diversity.
Maximum likelihood phylogenetic trees were generated by using PhyML
(26) and visualized by using Figtree v.1.2.2 (http://tree.bio.ed.ac.uk
/software/figtree). HIV-1 sequences from chronically infected individuals
were previously deposited into the GenBank database (15).
Site-directed mutagenesis. NL4-3 integrase was subcloned into a
TOPO-TA vector (Invitrogen), and the mutations S119R and A91E were
introduced either alone or in combination by site-directed mutagenesis
using the QuikChange XL kit (Stratagene) and custom-designed primers.
After verification by DNA sequencing, mutant integrase sequences were
amplified from plasmid DNA, and recombinant viruses were generated
and assayed as described above.
Identification of HLA-associated polymorphisms and covarying
sites. HLA-associated polymorphisms and their respective covarying
polymorphic sites in integrase were defined based on a previously re-
ported analysis of plasma HIV RNA sequences from the International
HIV Adaptation Collaborative, comprised of 1,317 antiretroviral-naïve,
chronically infected individuals from cohorts in Canada, the United
States, and Australia (97.5% subtype B) (15). All polymorphisms that
were significant at a q value of	0.2 are shown Fig. 4.
Prediction of novel HIV-1 epitopes and associations with RC. To
investigate HLA-associated polymorphisms linked to reduced RC that
were not located within or near a previously reported CTL epitope, we
examined gamma interferon (IFN-
) enzyme-linked immunosorbent
spot (ELISpot) assay responses from 372 HIV-positive (HIV) individu-
als screened with overlapping subtype B consensus peptides 15 to 18
amino acids in length spanning the integrase protein (22; our unpublished
data). Fisher’s exact test was used to assess whether the expression of the
HLA class I allele restricting the polymorphism of interest was signifi-
cantly associated with the targeting of the respective overlapping peptide,
evidence which would support the existence of a novel epitope within this
peptide. Sequences of significantly reactive overlapping peptides were
then scanned by using the bioinformatic epitope prediction algorithms
NetCTL (36) (for HLA-B alleles) and Epipred (27a) (for HLA-B and -C
alleles) to predict the most likely CTL epitope.
Gamma interferon ELISpot assays and C*05 epitope mapping.
Epitope mapping and HLA restriction were conducted as previously de-
scribed (23). Thirty-one integrase peptides overlapping the region of the
HLAC*05-associated polymorphism at position 119 were used for IFN-

ELISpot assays at 20 g/ml to stimulate peripheral blood mononuclear
cells (PBMC) (100,000 cells/well) from patient F702 (HLA-A*02, -A*30,
-B*53, -B*58, -C*04, and -C*05). The magnitude of each response was
determined as the number of spot-forming cells (SFC) per million input
cells and was measured by using a CTL-ImmunoSpot automatic ELISpot
reader (CTL, Bonn, Germany). The threshold for positive responses was
defined as the highest of the following three criteria: aminimumof 5 spots
per well, the mean number of SFC of the negative-control wells plus three
times its standard deviation, or three times the mean of negative-control
wells. Further fine mapping was performed by titrating peptides that elic-
ited a positive response in serial 10-fold dilutions in ELISpot assays, with
peptide concentrations ranging from 20 g/ml to 0.2 ng/ml.
Statistical analysis. The Mann-Whitney U test was used to compare
differences in replication capacities between groups (e.g., the presence
versus the absence of HLA alleles or the presence versus the absence of
specific viral polymorphisms). The relationship between RC and the
number of HLA-associated escapemutations or clinical parameters (CD4
and plasma viral load [pVL]) was assessed by using Spearman’s correla-
tion. In exploratory analyses of integrase polymorphisms associated with
RC, multiple tests were addressed by using a q value approach (56).
Nucleotide sequence accession numbers. Accession numbers for the
acute/early sequences are JQ080085 to JQ080172.
RESULTS
Construction of recombinant viruses from integrase samples
from early and chronic infections. In order to assess the potential
impact of HLA-mediated immune pressure on integrase activity,
we developed a recombinant viral assay to measure the in vitro
replication capacity (RC) of patient-derived plasma HIV-1 inte-
grase RNA sequences. Integrase recombinant viruses were gener-
ated from 88 early and 304 chronic HIV-1 subtype B-infected
antiretroviral-naïve individuals (Table 1), using methods de-
signed to capture in vivo quasispecies diversity (8, 42). Recombi-
nant viral stocks were resequenced to confirm patient origin and
to assess sequence diversity. As expected, bulk plasma HIV RNA
and recombinant virus sequences from early infection displayed
limited diversity:70% of plasma and recombinant viruses were
apparently clonal (i.e., they displayed no mixtures at the amino
acid level). Plasma and recombinant viral sequences from chronic
infection displayed higher levels of diversity: 23% and 33%, re-
spectively, were clonal at the amino acid level. Recombinant vi-
ruses were highly concordant with the input PCR product: a me-
dian of 0 (IQR, 0 to 0) (out of 288) full amino acid differences in
integrase were observed between plasma and recombinant viral
sequences.
In vitro RC was determined for each recombinant virus by
using a GFP-reporter T-cell assay (8, 42), and the results were
normalized to those of the parental NL4-3 strain such that RC
values of 1.0 signify replication equivalent to that of NL4-3,
whereas values of 	1 or 1 indicate a lower or higher RC than
that of NL4-3, respectively. Median RC values were comparable
between early and chronic cohorts (medians of 0.99 [IQR, 0.92 to
1.04] for early viruses and 1.01 [IQR, 0.96 to 1.04] for chronic
viruses; P  0.1 by Mann-Whitney U test), indicating that on
average, the in vitro function of patient integrase sequences was
comparable to that of NL4-3 regardless of the time since infection
(Fig. 1). Median RCs of early and chronic viruses encoding clonal
integrase sequences (n 58 and n 99, respectively) versus those
of viruses containing at least one amino acid mixture (n 30 and
FIG 1 Integrase replication capacities of early and chronic samples. NL4-3
normalized replication capacities (RC) of recombinant viruses expressing in-
tegrase from 88 patients with early infection and 304 patients with chronic
infection are indicated with Tukey box plots. Box boundaries display the me-
dians and interquartile ranges, whiskers display maximum andminimum val-
ues excluding outliers, and outliers (defined as greater than 1.5 times the in-
terquartile distances) are shown as points. No significant difference in
integrase RC was observed between cohorts (P  0.1 by Mann-Whitney U
test).
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n  205, respectively) were also comparable (P  0.1 by Mann-
Whitney U test) (data not shown), demonstrating that results
were not confounded by differences in the quasispecies diversity
of recombinant viral stocks.
Modest relationship between HLA class I-associated pres-
sure and integrase replication capacity. To assess the potential
consequence of HLA-mediated selection pressure on integrase
function during natural infection, recombinant viral RC values
were stratified according to host HLA-A, -B, and -C allele expres-
sion genotypes and analyzed in both early and chronic infection
cohorts (Fig. 2). In a systematic pairwise analysis of viral RC in
early samples, host expression of HLA-B*07, -B*15, and -C*02
were each independently associated with modestly lower RC val-
ues than those for individuals not expressing these alleles, while
C*15 was associated with modestly higher RC values than those
for individuals not expressing this allele (all P 	 0.05 by Mann-
Whitney U test); however, these associations did not remain sig-
nificant after correction for multiple comparisons (all q  0.4).
Integrase RC did not correlate significantly with the estimated
time since infection either overall (n  88; Spearman R  0.15;
P 0.16) or in analyses restricted to protective alleles only (B*27,
B*51, B*57, and/or B*58) (n 25; SpearmanR0.3;P 0.16).
In a systematic pairwise analysis of chronic viral RC for eachHLA,
the host expressions of A*23, B*58, and C*12 were associated with
modestly lower RC values, while A*29 and B*07 were associated
withmodestly higher RC values (all P	 0.05 byMann-WhitneyU
test); however, these associations were not significant after correc-
tion for multiple comparisons (all q  0.35). We observed no
FIG 2 Limited evidence for HLA-associated attenuation of integrase during natural HIV-1 infection. The viral replication capacities (RC) of early integrase
samples (A to C) and of chronic integrase samples (D to F) were stratified according to the HLA-A (A and D), HLA-B (B and E), and HLA-C (C and F) allele
expression of the host. Results are displayed as box plots, arranged bymedian RC from lowest (top) to highest (bottom). Box boundaries display themedians and
interquartile ranges, and whiskers display maximum andminimum values. HLA associations with RC are indicated by asterisks (P	 0.05 by Mann-Whitney U
test).
Brockman et al.
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significant associations between integrase RC and plasma viral
loads (pVL) (R 0.03; P 0.6) or CD4 counts (R0.03; P
0.7) for samples from chronic infections. Recombinant viruses
encodingGag-protease had been constructed previously for a sub-
set of chronic patients (n  284) (8); however, no correlation
between integrase and Gag-protease-mediated RC was observed
(R 0.03; P 0.6).
Limited impact of known HLA-associated mutations on in-
tegrase replication capacity. To explore the relationship between
known HLA-associated mutations and the integrase RC, we em-
ployed a previously reported list of HLA-associated HIV-1 sub-
type B polymorphisms, derived through statistical analyses of a
cohort of 1,317 antiretroviral-naïve individuals with chronic in-
fection (15). For each recombinant viral sequence, we determined
the total number of HLA-associated polymorphisms according to
the patient’s six HLA class I alleles. In samples from early infec-
tion, we observed no correlations between the total number of
HLA-A-, -B-, or -C-associated polymorphisms specific for the pa-
tient’s HLA and RC (data not shown). For samples from chronic
infection, we observed a modest yet statistically significant nega-
tive correlation between the total number of HLA-B-associated
integrase polymorphisms and viral RC (R  0.2; P  0.003),
while no correlation was seen for either HLA-A- or HLA-C-asso-
ciatedmutations (data not shown). Further analyses of theHLA-B
locus revealed no significant relationships between RC and the
number of integrase mutations associated with any single allele
(data not shown), suggesting an additive negative effect of muta-
tions selected by multiple HLA-B alleles on protein function.
Identification of integrase amino acids associated with viral
replication capacity. We next performed an exploratory codon-
by-codon analysis of integrase sequences in the chronic and the
combined (early plus chronic) data sets in order to identify poly-
morphisms that were significantly associated with viral RC. Note
that this investigation did not consider hostHLA allele expression,
and therefore, it may identify transmitted polymorphisms as well
as de novo CTL escape mutations. We observed that the integrase
polymorphisms K111Q, S119R, G163E, D167E, K188R, K215X,
I220L, and Y227X were each linked with lower RC (all P	 0.05)
(Table 2), while the D6E and S283G polymorphisms were each
linked with higher viral RC (P 	 0.05). To assess the potential
additive effects of these 10 polymorphisms on integrase function,
we stratified viral RC according to the number of mutations en-
coded by each patient’s sequence (0 to 5) and observed a statisti-
cally significant inverse correlation (Spearman R  0.35; P 	
0.0001) (Fig. 3).
Notably, 8 (out of 10) of these variants represent polymor-
phisms that are significantly associated with host HLA expression
based on population-level studies (15) (Table 2 and Fig. 4), sug-
TABLE 2 Exploratory analysis of integrase polymorphisms and viral RCa (P	 0.05)
Cohort
Integrase
codon aa
No. of
patients
with aa
No. of
patients
without
aa
Median RC
with aa
Median RC
without aa P value q value
HLA
associationb HLA-restricted epitope(s)
Response
frequency
(%)c
Chronic S119 R 12 292 0.94 1.01 0.0001 0.02 C*05 HTDNGSNF (confirmed) 18
Chronic D167 E 5 299 0.94 1.01 0.028 0.45 C*18 VRDQAEHL ND
Chronic K188 K 298 6 1.01 0.93 0.006 0.35 Consensus
Chronic K188 R 6 298 0.93 1.01 0.014 0.35 B*27 and C*02 KRKGGIGGY (B*27),
NFKRKGGI (C*02)
(predicted)
59, 62
Chronic K215 K 298 6 1.01 0.93 0.021 0.44 Consensus
Chronic I220 I 292 12 1.01 0.95 0.012 0.35 Consensus
Chronic I220 L 8 296 0.95 1.01 0.013 0.35 B*52 KQITKIQNF, KIQNFRVYY
(predicted)
ND
Chronic Y227 Y 299 5 1.01 0.93 0.032 0.45 Consensus
Chronic S283 G 17 287 1.03 1.00 0.032 0.45 None
Merged D6 D 376 16 1.00 1.04 0.021 0.34 Consensus
Merged D6 E 16 376 1.04 1.00 0.021 0.34 B*44 QEEHEKYHSNW 13
Merged K111 Q 5 387 0.93 1.00 0.026 0.35 None
Merged S119 R 12 380 0.94 1.01 0.001 0.13 C*05 HTDNGSNF (confirmed) 18
Merged G163 E 26 366 0.95 1.01 0.003 0.14 A*33 ELKKIIGQVR 20
Merged G163 G 368 24 1.01 0.95 0.004 0.14 Consensus
Merged D167 D 386 6 1.00 0.94 0.010 0.25 Consensus
Merged K188 K 384 8 1.00 0.93 0.014 0.30 Consensus
Merged K188 R 8 384 0.93 1.00 0.024 0.35 B*27 and C*02 KRKGGIGGY (B*27),
NFKRKGGI (C*02)
(predicted)
59, 62
Merged K215 K 386 6 1.00 0.93 0.033 0.41 Consensus
Merged I220 I 376 16 1.01 0.95 0.005 0.14 Consensus
Merged I220 L 13 379 0.95 1.01 0.002 0.13 B*52 KQITKIQNF, KIQNFRVYY
(predicted)
ND
a The analysis is restricted to polymorphisms with a frequency greater than or equal to 5. Codon associations that are significant (q values of	0.2) are indicated using boldface type.
Abbreviations: aa, amino acid; RC, replication capacity; ND, not determined.
b Based on data from reference 15.
c Frequency of positive IFN-
 ELISpot responses to overlapping 18-mer peptides in individuals expressing the indicated HLA.
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gesting that immune pressure on integrase can contribute to viral
RC in some cases. Further data exploration revealed that polymor-
phisms located at previously identified HLA-associated sites
tended to be more costly to integrase RC than polymorphisms
located at non-HLA-associated sites (P  0.018) (data not
shown). In addition, known epitope-specific CTL responses were
reported previously to overlap several of these mutations, includ-
ing D6E (B*44-QW11) (15, 54), G163E (A*33-ER10) (15, 35),
D167E (C*18-VL8) (5, 15, 38), and K188R (B*27-KY9) (47).
However, all of these polymorphisms are observed infrequently
(	7% frequency at the population level) (15), suggesting that
these epitopes are rarely targeted by CTL and/or that these poly-
morphisms represent uncommon pathways of CTL escape.
Of the polymorphisms identified here, the S119R (C*05),
G163E (A*33), and I220L (B*52) polymorphisms remained sig-
nificant after correction for multiple comparisons (all q 	 0.2)
(Table 2). The stratification of viral RC according to the number
of these mutations that were encoded by patient sequences (0, 1,
or 2) demonstrated an inverse correlation, indicating that these
three polymorphisms could contribute additively to integrase
function (SpearmanR0.31;P	 0.0001) (data not shown). As
noted above, theG163E polymorphism is likely to be driven by the
knownCTL response directed against the A*33-ER10 epitope (15,
35). Despite strong statistical associations linking C*05 with the
S119R polymorphism and B*52 with the I220L polymorphism
(15), no CTL epitopes restricted by these alleles have been defined
in these regions. To investigate the existence of novel epitopes, we
analyzed IFN-
ELISpot responses to overlapping 18-mer subtype
B consensus integrase peptides in 372 chronically infected indi-
viduals (22; our unpublished data). We applied Fisher’s exact test
to assess whether the expression of each HLA was significantly
associated with host responses to a peptide(s) containing the po-
sition of interest, and we used the bioinformatics tools Epipred
and NetCTL (36) to predict the most likely epitope sequences. In
our data, the expression of C*05 (n  33) was significantly asso-
ciated with IFN-
 reactivity to two overlapping peptides in this
region: AGRWPVKTIHTDNGSNF105–121 (odds ratio [OR], 6.4;
P  0.003) and TIHTDNGSNFTSTTVKAA112–129 (OR, 7.2; P 
0.01). Bioinformatics analysis suggested that themost likely C*05-
restricted epitope sequence in the overlapping region was IHTD
NGSNF (HXB2 positions 113 to 121; Epipred score, 4.69). In-
sufficient ELISpot data were available for B*52 individuals;
however, bioinformatics analysis suggested that KQITKIQNF
(HXB2 positions 215 to 223; Epipred score,3.26; NetCTL value,
104 nM) or KIQNFRVYY (HXB2 positions 219 to 227; Epipred
score, 3.22; NetCTL value, 423 nM) was the most likely B*52-
restricted epitope in this region. The location of each epitope and
the frequency of positive IFN-
 ELISpot responses to long pep-
tides are indicated in Fig. 4 and Table 2, respectively.
Confirmation of a novel C*05 epitope spanning integrase
codon S119. Very fewC*05-restricted epitopes have been described.
Asa result, epitopepredictionalgorithms for this allele are limited.To
confirm our prediction that a novel C*05 response may drive viral
escape at integrase position S119, we used IFN-
 ELISpot assays to
test a panel of shorter peptides spanning codons 105 to 129 in PBMC
from a C*05-expressing individual who displayed reactivity in this
region. We observed a loss of IFN-
 reactivity in PBMC for all pep-
tides that did not have the sequenceHTDNGSNF114–121, indicating
that this 8-mer peptide was the minimal C*05-restricted epitope
(Fig. 5). Peptide titration assays demonstrated that the half-max-
imal stimulatory dose (SD50) forHTDNGSNF114–121 (10ng/ml)
was substantially lower than that for other peptides spanning this
sequence, including the predicted sequence IHTDNGSNF113–121,
illustrating that this 8-mer peptide is the optimal C*05 epitope in
this region of integrase.
Validation of impaired replication by the S119R polymor-
phism and its compensation by the A91E mutation. The C*05-
restricted polymorphism S119R was most significantly associated
with lower RC in chronic patient sequences (P 0.0001; q 0.02)
(Table 2). To validate this result, we generated an NL4-3 site-
directedmutant encoding the S119R polymorphism and tested its
function. In vitro assays revealed that the S119R virus exhibited a
35% lower RC than did the parental NL4-3 strain (Fig. 6), dem-
onstrating that this mutation alone could substantially diminish
integrase function.
The in vitro RC defect displayed by the S119R site-directed
mutant was notably greater than the average 7% lower RC ob-
served for patient isolates that encoded this polymorphism. We
therefore hypothesized that the S119R mutation could be com-
pensated for by a secondary mutation(s) present in clinical se-
quences. Putative S119R compensatorymutations were identified
by using previously reported data for covarying amino acids in
HIV-1 integrase, generated using the same large cohort used to
identify HLA-associated integrase polymorphisms at the popula-
tion level (15). The residue most strongly covarying with the
S119Rmutation in patient sequenceswas the upstreamA91E vari-
ant (P 3.48 1015; q 1.26 1011) (data not shown), which
lies 12.5 Å away from codon 119 on an adjacent loop in the
three-dimensional integrase protein structure (Fig. 6B).
We constructed additional site-directed mutants expressing
the A91E variant alone as well as the A91E variant in combination
with the S119R variant. Themutant expressing theA91Emutation
alone exhibited a similar35% lower RC than that of the parental
NL4-3 strain; however, the combination of both the A91E and
S119R mutations restored integrase RC to wild-type levels (Fig.
6A). Consistent with these results, the stratification of patient-
derived S119R-containing integrase recombinant viruses into
those expressing the S119R mutation only (n  10) versus those
expressing both the S119R and A91E mutations (n 2) revealed
higher RC when these two mutations were present together (Fig.
6C). The A91E mutation alone was not observed for any patient
FIG 3 Additive effect of integrase polymorphisms on viral replication capac-
ity. The viral replication capacities (RC) were stratified according to the total
number of polymorphisms (E6D, K111Q, S119R, G163E, D167E, K188R,
K215X, I220L, Y227X, and G283S) (all P 	 0.05) (Table 2) encoded by each
patient-derived sequence. A significant inverse association between viral RC
and the number of polymorphisms was observed (Spearman R0.35; P	
0.0001).
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samples in our study. Together, these data demonstrate that re-
duced integrase function was observed for the C*05-associated
S119R mutation and that this defect can be compensated for by a
naturally occurring secondary mutation, A91E.
DISCUSSION
Despite the presence of immunogenic CTL epitopes in integrase
restricted by protective HLA class I alleles and the reproducible
patterns of immune escape in large-scale studies of infected indi-
viduals, our results indicate that the immune-driven attenuation
of HIV-1 integrase function is not a general phenomenon during
natural infection. In contrast to previous studies of recombinant
viruses expressing Gag-protease (8, 31, 64), the range of integrase
RC values observed in this study was relatively narrow, indicating
that patient-derived sequences were in general highly functional.
Nevertheless, we observed that polymorphisms atHLA-associated
sites were more costly than those at non-HLA-associated sites,
identified several HLA-associated polymorphisms that correlated
FIG 4 Integrase immune escape map. HLA-associated polymorphisms, known and predicted CTL epitopes, and mutations associated with reduced viral
replication capacity (RC) are indicated along the linear sequence of theHIV-1 integrase protein. HLA-associated polymorphisms (all q	 0.2) were defined based
on an analysis of 1,317 antiretroviral-naïve, chronically infected individuals from cohorts in Canada, the United States, and Australia (97.5% subtype B) (15).
Shaded vertical bars separate blocks of 10 amino acids. KnownCTL epitopes and restrictingHLA class I alleles are indicated above the sequencewith black arrows
and text, as reported by theHIVMolecular Immunology Database (www.hiv.lanl.gov). Putative CTL epitopes and restrictingHLA alleles are indicated above the
sequence with green arrows and text, as predicted in this study. The C*05-restricted HTDNGSNF (HF8) epitope, validated in this study, is indicated above the
sequence with red arrows and text. HLA-associated polymorphisms are shown below the protein sequence: “adapted” amino acids (enriched in the presence of
the HLA allele) are displayed in red text, and “nonadapted” amino acids (enriched in the absence of the HLA allele) are displayed in blue text. Uppercase letters
distinguish polymorphisms that survive correction for codon covariation. Polymorphisms associated with the same HLA allele that occur in proximity to one
another are grouped together in yellow boxes. Amino acid residues associated with integrase RC are indicated by , and the compensatory site A91 is noted by
Œ. Red boxes highlight the essential catalytic-site amino acids D64, D116, and E152.
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with reduced RC, and confirmed a novel C*05-restricted epitope
thatmay contribute to this effect. Together, these data suggest that
immune pressure can select for sequence variants that compro-
mise integrase function and reduce viral fitness.
FIG 6 Confirmation of integrase S119R-mediated attenuation and its com-
pensation by the A91E variant. (A) NL4-3 site-directed mutants encoding
integrase mutations A91E and S119R, either alone or together, were con-
structed, and their in vitro replication capacities (RC) were assessed as de-
scribed inMaterials andMethods. Viral RCwas impaired by either theA91E or
S119R mutation alone, but RC was restored to wild-type levels when these
mutations were introduced together. (B) The positions of residues A91 and
S119 are indicated in the three-dimensional structure of the integrase protein
(Protein Data Bank [PDB] accession number 1K6Y [62]). The three essential
catalytic-site residues, D64, D116, and E152, are also highlighted. (C) In vitro
RC results for integrase recombinant viruses encoding the S119R mutation
only (n  10) versus results for viruses encoding the S119R and A91E muta-
tions (n 2) indicate higher RC when these mutations are observed together
in patient-derived sequences.
FIG 5 Detection of a novel C*05 epitope at integrase positions 114 to 121. (A)
ELISpot assays were used to test PBMC from C*05 patient F702. IFN-
 spot-
forming cells (SFC) per 106 PBMCafter the subtraction of negative-control values
are shown on the right. Positive responses (shaded) were determined as described
inMaterials andMethods. Aligned sequences indicate IFN-
 reactivity against the
minimal peptide HTDNGSNF114–121 (HF8) (shown in boldface type). (B) Se-
rial dilutions of peptides spanning codons 112 to 126 were used to stimulate
PBMC from patient F702. Responses to the predicted peptide (IHTDNSNF)
are indicated by the green line (open diamonds). The HF8 peptide (red line
and closed diamonds) displayed the lowest SD50 value, and it is therefore
proposed to be the optimal epitope presented by C*05.
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Significant reductions in RC were observed in the context of
certain HLA-associated mutations, of which the S119R, G163E,
and I220L mutations were most prominent. These polymor-
phisms are selected byHLA class I alleles that are not considered to
be protective, including C*05, A*33, and B*52, respectively. A
previous study by our group featuring RT-integrase sequences
derived from HIV-1 elite controllers identified an association be-
tween integrase codon 265 and lower RC (16); however, this was
not observed in the present study. Notably, these attenuating mu-
tations were not restricted by protectiveHLA alleles. Rather, poly-
morphisms that were significantly associated with RC were tar-
geted by nonprotective alleles that have not beenwidely studied in
the context of vaccine design. Since the majority of individuals in
a population will not express a protective HLA class I allele, the
development of a broadly effective CTL-based vaccine will likely
require the design of immunogens that can stimulate host re-
sponses restricted bymore common alleles (44). Our observations
are therefore encouraging, since they support the notion that non-
protective HLA may be harnessed to more effectively target vul-
nerable regions of HIV-1, including sites in the integrase gene.
The integrase polymorphisms S119R and I220L are likely to
lie within novel CTL epitopes restricted by HLA-C*05 and
-B*52, respectively. Using functional (IFN-
 ELISpot) and
computational approaches, we identified putative candidate
epitope sequences at both positions. We validated one predic-
tion by mapping a new optimal epitope (HTDNGSNF114–121) in
a C*05-expressing individual which spans position S119. This re-
sult highlights the utility of combining sequence-based analyses of
population-level immune escape with large-scale functional anal-
yses to guide vaccine discovery for novel HIV-1 epitopes, partic-
ularly for viral proteins outside Gag and for HLA alleles that are
not typically considered to be protective (2, 4).
Using site-directed mutagenesis, we confirmed that the most
significant association identified using patient sequences, the
S119R mutation, displayed a35%-reduced RC when it was en-
gineered alone into laboratory-adapted isolate NL4-3. We also
identified a secondary mutation, A91E, which restored RC to
wild-type levels in NL4-3 and which appeared to compensate for
the S119R mutation in 2 out of 12 patient sequences. Covariation
between integrase codons 91 and 119 was reported previously
(52), although functional studies to test their interaction have not
been performed previously. Notably, the impact of the S119Rmu-
tation on RC was substantially greater for NL4-3 than for patient-
derived recombinant viruses, and the A91Emutation appeared to
contribute to RC recovery in only a few cases. This finding
strongly suggests that alternative mechanisms of S119R compen-
sation exist; however, to date, we have not been able to identify
additional pathways using our data.
Mutations at HIV-1 integrase codon 119 are known to affect
integration site selection (27). A recent high-resolution structure
of the prototype foamy virus (PFV) integrase bound to viral and
target DNA demonstrated that residue A188 (which is homolo-
gous to HIV-1 integrase codon 119) formed a van der Waals in-
teraction with a key cytosine in the minor groove of the target
DNA sequence (40). The reduced viral RC that we observed with
the S119R mutation is therefore consistent with a defect in inte-
grase function at the step of target site recognition and strand
transfer. Specifically, our data suggest that the substitution of a
positively charged amino acid at this position (arginine) may be
more costly to integrase function than the more conservative
changes that have been analyzed previously, such as threonine,
glycine, or alanine (27). More detailed studies will be required to
confirm this hypothesis and to assess themechanism by which the
A91E mutation compensates for the S119R mutation. Similarly,
additional work will be necessary to examine the other integrase
mutations identified in this study, including assays to directly as-
sess in vitro enzymatic activity. Codon K188, which is part of the
KRKmotif (residues 186 to 188), forms a salt bridge withD25 that
stabilizes themultimer structure, and itmay participatewithK215
and I220 in dimerization and viral DNA binding (18, 37), but
putative roles for codons D6, K111, G163, D167, Y227, and G283
have not been described. The generally conservative nature of
amino acid substitutions observed at these sites suggests impor-
tant structural contributions of these amino acids (52).
Our analyses of integrase did not identify a consistent HLA
allele or common HLA-associated polymorphism that contrib-
uted substantially to RC. Rather, we observed a small number of
infrequent polymorphisms that appeared to compromise RC.
Since our study of 392 recombinant viruses is well powered to
assess frequent cases, our results indicate that immune selection
pressure on integrase can result in a functional impairment that
affects viral RC. However, the specific HLA-associated polymor-
phisms identified appear to be relatively rare escape mutations at
the population level. For example, the S119Rmutation is likely to
represent the less commonof two possible escapemutations in the
C*05-restricted HTDNGSNF epitope described here. In a large
cohort of infected individuals (15), the S119R mutation was ob-
served for 13.9% of C*05-expressing individuals, while the more
common S119P variant (which was not associated with lower RC
in our study) was observed for 40.2% of persons expressing C*05.
Such differences in the frequency of escape mutations can be at-
tributed to a variation in host CTL pressure (i.e., antigen receptor
clonotypes) or intrinsic barriers to incorporating changes in the
context of the founder viral protein sequence (i.e., the presence of
secondary mutations that reduce fitness costs). To best utilize
functional information for vaccine design, it may be necessary not
only to enhance the frequency of CTL responses in persons ex-
pressing the relevant HLA but also to devise novel strategies that
channel HIV-1 evolution in favor of mutations that reduce viral
fitness. Indeed, the design of vaccine immunogens that incorpo-
rate both the wild-type sequence as well as the preferred escape
variant(s) represents one feasible approach to achieve this end (4,
7, 14).
Several other caveats and limitations of this study merit men-
tion. First, our experimental design utilized recombinant viruses
that focused on a single gene product, and as such, potential epi-
static interactions with other viral proteins that could affect RC
have not been taken into account (17, 28). Indeed, false-positive
(and false-negative) results could arise due to the choice of NL4-3
as a backbone vector for this work, and studies using other viral
strains andwhole-virus isolatesmay be necessary to determine the
full impact of the polymorphisms identified here on viral fitness.
Second, the relative reductions in viral RC observed for patient-
derived sequences weremodest, particularly in comparison to our
previous results for Gag. This might be attributed to the relative
sequence conservation of integrase (65) and its essential enzy-
matic role in the HIV-1 replication cycle. Notably, data from a
recent report (49) indicated that the three codons associated with
RC in our study demonstrate a higher degree of polymorphism
than other integrase codons, S119 (7.5% nonconsensus amino
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acids), G163 (1.8%), and I220 (1.8%), versus a median integrase
value of 0% (IQR, 0 to 0.5) (P 0.006) (not shown). Finally, we
did not observe a significant correlation between RC and clinical
measures of HIV-1 infection (pVL and CD4 count). This may be
due in part to the integrase-focused experimental design, the rel-
atively progressed status of our chronic cohort, the small number
of polymorphisms identified that were associated with integrase
function, and the ability of secondary mutations to compensate
for impaired RC in some cases. Despite these limitations, we were
able to uncover HLA-associated polymorphisms that may con-
tribute to integrase function, we confirmed the functional impact
of our top hit (S119R) and a compensatory mechanism (A91E)
using site-directed mutants, and we identified a novel C*05-re-
stricted CTL response that is likely to contribute to these observa-
tions.
In summary, the HLA-mediated impairment of HIV-1 inte-
grase does not appear to be a general phenomenon during viral
adaptation to host immune responses. Nevertheless, we identified
uncommon immune-driven polymorphisms that were associated
with reduced viral RC. Attenuating mutations were restricted by
HLA class I alleles that are not conventionally regarded as being
protective, including the S119Rmutation,which is situatedwithin
a novel C*05 epitope. This study highlights the potential utility of
population-based functional studies for immunogen discovery.
Indeed, from a vaccine perspective, it is encouraging to uncover
new examples of viral mutations selected by nonprotective HLA
alleles that may be able to reduce HIV-1 fitness. The data pre-
sented here suggest that certain integrase epitopes could be con-
sidered for vaccine strategies designed to diminish HIV-1 patho-
genesis.
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